drugset

drugset / Trial / NCT07616128

Study of EVO756 in Adults With Migraine

NCT07616128 ↗

Phase 2 Recruiting 330 enrolled Evommune, Inc.

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

Timeline

Start: 2026-06
Primary completion: 2027-10
Completion: 2027-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVO756	Unknown	—	Oral

Indications